Leading Generic Company Selects Model N for Rebate and Incentive Management in Europe

Share Article

Selection Highlights Growing Adoption of Model N's Best-in-Class Solutions in the European Market

This selection reflects the continued high demand for Model N's proven, integrated Revenue Management solutions from pharma and med tech manufacturers across the globe

Model N, Inc., the leader in Revenue Management solutions, today announced that a leading generic drug manufacturer has selected Model N for management of Rebates and Incentives and will begin implementation of Model N's Rebates solution in the Netherlands. The Model N selection came after a comprehensive evaluation of several alternative solutions against the customer's European requirements and the ability to scale the solution across operations.

Model N has several marquee pharma and med tech customers currently implementing solutions in Europe. During the course of the evaluation, Model N's investment in product capabilities for the European market coupled with local resources and experience with Europe-wide implementations provided the customer with the confidence to invest in this Revenue Management system. In addition, Model N will integrate with and complement the customer's ERP system to automate rebate accruals and payments management, improve contract flexibility, shorten rebate processing cycle times, and provide a full audit trail to enhance financial accuracy and compliance.

"This selection reflects the continued high demand for Model N's proven, integrated Revenue Management solutions from pharma and med tech manufacturers across the globe," said Niels Skov, Managing Director, Model N Europe. "The deployment will give the company a standard platform for Revenue Management in Europe that delivers flexibility at the country level to address the needs of each unique market."

About Model N
Model N is the leader in Revenue Management solutions, offering an integrated suite of applications for analytics, pricing, contracts, compliance, and settlements optimized for the industry practices of Life Science and High Tech companies. Enabling the creation of a seamless, end-to-end process from price setting through settlements payment, Model N's uniquely integrated approach eliminates revenue leakage and delivers the visibility and controls needed to avoid the risks of non-compliance. Customers include: Atmel Corp.; Boston Scientific Corp.; Bristol-Myers Squibb Company; Cypress Semiconductor; Medtronic, Inc.; Microchip Technology Inc.; Ortho-Clinical Diagnostics, a Johnson & Johnson company; Pfizer, Inc.; and STMicroelectronics. Model N is headquartered in Redwood Shores, California, and has offices across the U.S., as well as Europe and India. For additional information, visit http://www.modeln.com.

Model N is a mark of Model N, Inc. All other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sean Cassidy
Visit website